The interim numbers are jaw-dropping: 41 months PFS for T-DXd + pertuzumab versus 27 months for THP, with overall-survival curves already fanning out. Dr. Mouabbi calls it the first regimen to stretch the calendar rather than just the curve with the results still on track to grow.
41-Month PFS: New Gold Standard
Recommended Videos
